
1 **Association of Visual Impairment with Risk for Future Parkinson's Disease**

2

3 **Running title:** VI and Parkinson's disease

4

5 **Authors**

6 Zhuoting Zhu, MD PhD¹

7 Wenyi Hu, MBBS²

8 Huan Liao, MD³

9 Zachary Tan, MBBS MMed⁴

10 Yifan Chen, BM BCh⁵

11 Danli Shi, MD⁶

12 Xianwen Shang, PhD^{1,4}

13 Xueli Zhang, PhD¹

14 Yu Huang, MD PhD¹

15 Honghua Yu, MD PhD¹

16 Wei Wang, MD PhD⁶

17 Mingguang He, MD PhD^{1,4,6}

18 Xiaohong Yang, MD PhD¹

19

20 **Affiliations**

21 1. Department of Ophthalmology, Guangdong Academy of Medical Sciences,

22 Guangdong Provincial People's Hospital, Guangzhou, China.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 2. Shanghai Jiaotong University, Shanghai, China.
- 24 3. Neural Regeneration Group, Institute of Reconstructive Neurobiology, University
25 of Bonn, Bonn, Germany.
- 26 4. Centre for Eye Research, University of Melbourne, East Melbourne, Victoria,
27 Australia.
- 28 5. John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust,
29 Oxford, UK.
- 30 6. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-
31 sen University, Guangzhou, China.

32

33 **Word count: Abstract: 252; Whole paper: 1980.**

34 **Tables: 3; Supplementary Table: 1**

35

36 **Corresponding authors**

37 Mingguang He, MD PhD

38 Email: mingguang.he@unimelb.edu.au

39 Xiaohong Yang, MD PhD

40 Email: syyangxh@scut.edu.cn

41 Wei Wang, MD PhD

42 Email: zoc_wangwei@yahoo.com

43

44 **Abstract**

45 **Background:** Although visual dysfunction is one of the most common non-motor
46 symptoms among patients with Parkinson's disease (PD), it is not known whether such
47 dysfunction predates the onset of clinical PD.

48 **Objectives:** To examine the association of visual impairment (VI) with the future
49 development of PD in the UK Biobank Study.

50 **Methods:** The UK Biobank Study is one of the largest prospective cohort studies of
51 health, enrolling over 500,000 participants aged 40-69 years between 2006 and 2010
52 across the UK. VI was defined as a habitual distance visual acuity (VA) worse than 0.3
53 LogMAR in the better-seeing eye. Incident cases of PD were determined by self report
54 data, hospital admission records or death records, whichever came first. Multivariable
55 Cox proportional hazard regression models were used to investigate the association
56 between VI and the risk of incident PD.

57 **Results:** A total of 117,050 participants were free of PD at the baseline assessment.
58 During the median observation period of 5.96 (interquartile range [IQR]: 5.77-6.23)
59 years, PD occurred in 222 (0.19%) participants. Visually impaired participants were at
60 a higher risk of developing PD than non-VI participants ($p < 0.001$). Compared with the
61 non-VI group, the adjusted hazard ratio was 2.28 (95% CI 1.29-4.04, $p = 0.005$) in the
62 VI group. These results were consistent in the sensitivity analysis, where incident PD
63 cases diagnosed within one year after the baseline assessment were excluded.

64 **Conclusions:** This prospective cohort study found that VI was associated with an
65 increased risk of incident PD, suggesting that VI may represent a prodromal feature of
66 PD.

67

68 **Key words:** visual impairment, Parkinson's disease, ageing

69

70 **Introduction**

71 Parkinson's disease (PD) is the second most prevalent neurodegenerative disease and
72 affects 2-3% of the global population aged over 65¹. The total burden of disease
73 associated with PD is increasing due to ageing populations, longer disease durations
74 and environmental and social risk factors². Relatively conservative estimates predict
75 over 12 million patients will be affected by PD globally by 2050³.

76

77 In addition to motor symptoms, clinical features of PD involve many non-motor
78 symptoms exacerbating overall disability⁴. Non-motor symptoms of PD have recently
79 received increased attention as they precede the onset of motor symptoms, and may act
80 as markers of preclinical stages of PD⁵. Visual dysfunction has been reported as one of
81 the most common non-motor symptoms, and increasing evidence has demonstrated
82 higher prevalence of this non-motor symptom in PD patients compared to healthy
83 controls⁶⁻⁹. It is yet unknown however whether visual impairment (VI), an important
84 indicator of visual dysfunction¹⁰, predates the onset of clinical PD. Further,
85 understanding the association between VI and future risk of PD may facilitate early
86 diagnosis and intervention of PD prior to manifestation of the full clinical syndrome.

87

88 In this context, we sought to examine the association of VI with risk of future PD
89 development using the UK Biobank, a community-based longitudinal sample.

90

91 **Methods**

92 **Study Sample**

93 Detailed procedures of the UK Biobank study have been described elsewhere¹¹. Briefly,
94 more than 500,000 participants aged between 40-69 years were recruited at 22
95 assessment centers across the UK from 2006 to 2010. Data on lifestyle, environment
96 and medical history were obtained using self-administered questionnaires. Physical
97 measurements and biological specimens including blood, urine and saliva samples were
98 also collected. Detailed follow-up of the health of participants was achieved through
99 linkage to national electronic health record datasets. Ophthalmic examinations for
100 baseline assessment were carried out from 2009 at six assessment centers. Participants
101 with available visual acuity (VA) data (n=117,252) were included in the present
102 analysis. Baseline characteristics of participants with and without VA data is shown in
103 Supplement Table 1. Relative to participants without VA data, those with available VA
104 data were more likely to be slightly older (56.8 vs. 56.4 years), of non-Caucasian
105 ethnicity, less materially deprived, non-smokers, non-drinkers, physically active,
106 diabetic, hypertensive, and less likely to use psychotropic medications. For analysis of
107 incident PD, participants diagnosed with PD prior to baseline assessment (n=174), and
108 those with self-reported PD at the baseline nurse interview (n=28) were excluded,
109 leading to a final cohort with 117,050 participants included for analysis.

110

111 **Standard Protocol Approvals, Registrations, and Patient Consents**

112 Access to the UK Biobank data was granted after registration. The application ID was
113 62443. The UK Biobank has obtained Research Tissue Bank approval from its Research

114 Ethics Committee recommended by the National Research Ethics Service (reference
115 11/NW/0382). Participants provided written informed consent.

116

117 **Assessment of Visual Acuity**

118 Detailed methods for VA testing in the UK Biobank study have been described
119 elsewhere¹². Habitual distance VA was measured using a logarithm of the minimum
120 angle of resolution (LogMAR) chart (Precision Vision, LaSalle, Illinois, USA).
121 Participants were tested at 4 meters with habitual correction if any, or at 1 meter if
122 participants were unable to read. Participants were required to read letters sequentially
123 from the top and the total number of correctly identified letters was converted to a
124 logMAR VA. Presenting VA worse than 0.3 logMAR units (equivalent to Snellen 20/40)
125 was defined as VI.

126

127 **Ascertainment of PD**

128 The algorithm for ascertaining PD in the UK Biobank Study could be found at in detail
129 elsewhere¹³. In brief, ascertainment of PD was based on self-reported data, diagnosis in
130 the hospital admissions data, or cause of death recorded in the national death register,
131 whichever was the earliest. Hospital admission data were retrieved from Health Episode
132 Statistics records (for participants from England and Wales) and the Scottish Morbidity
133 Records (for participants from Scotland). The National Health Service (NHS)
134 Information Centre, and the NHS Central Register Scotland were used to obtain the
135 date and causes of death for participants from England and Wales, and Scotland,

136 respectively. The UK Biobank study conducted a validation study on the accuracy of
137 code sources for identification of PD cases, which achieved a positive predictive value
138 (PPV) of 0.91 (95% confidence interval [CI], 0.83-0.96) when combining all sources
139 (self report, hospital admission records, and death records)¹³. Follow-up length was
140 calculated as the time interval between the date of baseline assessment and the censor
141 date, which is either the date of PD diagnosis, death, lost to follow-up or 1st March 2016.

142

143 **Covariates**

144 Consistent with previous studies¹⁴⁻¹⁷, covariates for the analysis of incident PD included
145 age at baseline assessment (continuous), sex (male/female), ethnicity (Caucasian and
146 non-Caucasian), the Townsend deprivation index (continuous), smoking (current
147 smoker, past smoker, and never), alcohol consumption (current and past/never drinker),
148 obesity (yes/no), physical activity (above moderate/vigorous/walking recommendation,
149 and not), history of stroke (yes/no), history of diabete mellitus (yes/no), history of
150 hypertension (yes/no), and the use of psychotropic medications (yes/no).

151

152 Obesity was defined as body mass index (BMI) ≥ 30 kg/m². History of diabete mellitus
153 was defined to include participants with either doctor-diagnosed diabetes, insulin
154 treatment or oral antidiabetic medications. History of hypertension was defined to
155 include participants with either doctor-diagnosed hypertension, antihypertensive agents
156 or measured systolic pressure ≥ 130 mmHg or diastolic pressure ≥ 80 mmHg. The

157 previous use of anti-depressive, anti-migraine and axiolytic medications was defined as
158 the use of psychotropic medications.

159

160 **Statistical Analysis**

161 We reported normally distributed variables as means and standard deviation (SD);
162 skewed variables as median and interquartile range (IQR), and categorical variables as
163 number and percentages. Unpaired t-test and Pearson's χ^2 test were used to compare
164 continuous and categorical variables, respectively. The log-rank test was used for
165 comparison of incident PD distributions between VI and non-VI groups. The risks of
166 incident PD associated with VI were evaluated using Cox proportional hazards models
167 for estimation of hazard ratio (HR) with 95% confidence interval (CI).

168

169 To minimize the possibility of including prevalent cases in the present analysis, a
170 sensitivity analysis was performed to exclude PD cases diagnosed in the year
171 immediately following baseline assessment. Schoenfeld residuals were used to test the
172 proportional hazards assumptions for Cox models and all variables were found to be
173 valid. Two-sided p values less than 0.05 were considered statistically significant. All
174 tests were conducted using Stata version 13 (StataCorp LLC, College Station, Texas
175 USA).

176

177 **Data Availability Statement**

178 The UK Biobank is an open-access resource to researchers through registration of
179 proposed research. This present study was approved and registered as study 62443 with
180 the UK Biobank resource.

181

182 **Results**

183 A total of 117,050 participants (mean [SD] age: 56.8 [8.11] years; female: 63,695
184 [54.4%]) who were free of PD at the baseline assessment were included in this present
185 analysis. Baseline characteristics of included participants are described in Table 1. A
186 total of 4,011 (3.43%) participants suffered from VI. The visually impaired participants
187 tended to be older, of non-Caucasian ethnicity, more materially deprived, current
188 smokers, non-drinkers, obese, and with a history of stroke, diabetes and hypertension.
189 There were no differences in other characteristics between the VI and non-VI group.

190

191 During the median follow up period of 5.96 (IQR: 5.77-6.23) years, a total of 222 cases
192 of PD were recorded. The incidence of PD in all participants was 0.19%, with 16
193 (7.21%) being in the VI group and 206 (92.8%) being in the non-VI group, respectively.
194 The log-rank test demonstrated a significant difference in the incidence of PD between
195 the VI and non-VI groups ($p < 0.001$). Baseline characteristics stratified by the incidence
196 of PD are shown in Table 2. The incident PD group consisted of a greater proportion of
197 participants that were of older age, male gender, non-smokers, less physically active,
198 with a history of hypertension, and use of psychotropic medications at the baseline
199 assessment compared to the non-PD group.

200

201 The risks of developing PD for participants with and without VI based on Cox
202 proportional hazard regression models are shown in Table 3. After adjusting for age,
203 gender and ethnicity, the presence of VI was significantly associated with a higher risk
204 of developing PD (HR=2.13, 95% CI: 1.27-3.56, p=0.004). The multivariable Cox
205 proportional hazard regression model indicated that VI was associated with a 2.28-fold
206 higher risk of developing subsequent PD (95% CI: 1.29-4.04, p=0.005). Similar
207 findings were observed in the sensitivity analyses which excluded participants with PD
208 cases diagnosed in the year immediately following baseline assessment (HR=1.93, 95%
209 CI: 1.07-3.49, p=0.029, Table 3).

210

211 **Discussion**

212 In this large community-based sample, we found that visually impaired individuals had
213 a 2.28 times greater risk of developing PD compared to those who did not have any VI.
214 Our findings suggest that VI may represent a prodromal feature of PD.

215

216 To the best of our knowledge, this is the first study to demonstrate that visually impaired
217 individuals are at a greater risk of developing future PD than those without. Of note, it
218 is well established that visual dysfunctions are common in PD. In a cross-sectional
219 study of the European population, PD patients had a greater than double increase in the
220 odds of having fair or poor eyesight⁹. A case-control study suggested that patients with
221 mild to moderate PD had poorer performance compared to control subjects in visual

222 perception tasks⁶. Worsened visual function as measured by visual acuity was also
223 identified in PD patients in a cross-sectional study⁷.

224

225 Even though the mechanisms underlying the association of VI and incident PD were
226 unclear, several plausible explanations had been raised. Firstly, the ‘bottom-up theory’
227 postulated that impairment of the retinal dopaminergic system might explain visual
228 abnormalities in PD¹⁸. Both animal and clinical studies had suggested that
229 dopaminergic retinal cell loss was commonly seen in PD¹⁹⁻²². Further, aggregates of α -
230 synuclein in the retina that mimicked the pathological process of PD, had been reported
231 to cause neurodegeneration of the dopaminergic cells in the retina²³. Secondly, the ‘top-
232 down’ theory might explain visual dysfunctions observed in PD. Support for this
233 hypothesis came from evidence which demonstrated specific dysfunctions of the visual
234 cortex in PD²⁴. The depletion of neurotransmitters such as GABA and dopamine, as
235 well as altered lipid metabolism in the visual cortex of PD patients, could account for
236 visual symptoms²⁵⁻²⁷. Thirdly, strong evidence in associations between ocular diseases
237 and PD might also account for the association between VI and the development of
238 future PD²⁸. Previous studies found that ocular diseases, such as glaucoma, cataract,
239 age-related macular degeneration and diabetic retinopathy²⁹⁻³¹, shared similar
240 pathogenesis^{32, 33}, risk factors^{18, 34} and proteomics profiles³⁵ with PD. Further studies
241 are warranted to confirm these speculations.

242

243 Our findings have an important implication for research and public health policy. In the
244 present study, VI was identified as a potential prodromal feature of PD and might serve
245 as a novel marker for the preclinical stages of PD, potentially enabling improved early
246 diagnosis and management for those at higher risk of subsequently developing the
247 disease. VA screening may be expanded beyond its current scope in the prevention of
248 sight-threatening disease.

249

250 The strengths of the present study include its large sample size, long-term follow-up
251 duration, and comprehensive adjustments for confounding factors. However, several
252 limitations should be considered. Firstly, the present analysis was solely based on
253 baseline VA. Further studies are needed to examine the impact of vision loss and/or
254 other aspects of visual dysfunction on future risk of PD. Secondly, we did not have
255 sufficient information to differentiate between causes of VI, thus preventing us from
256 investigating associations between specific causes of VI and the risk of developing PD.
257 Thirdly, due to the nature of an observational study, the causal relationship between VI
258 and incident PD cannot be confirmed. Thirdly, the UK Biobank participants were
259 relatively younger and might not represent the whole population. Nevertheless, this
260 would not affect the association between VI and incident PD³⁶. Lastly, we could not
261 completely exclude the possibility of residual confounding.

262

263 **Conclusions**

264 In summary, we found that VI was associated with a significantly increased risk of
265 developing PD. Our findings highlighted the importance of vision screening in
266 identifying individuals at high risk of developing PD. Further studies are needed to
267 confirm our results, and the causal nature of VI and PD.

268

269 **Abbreviations and Acronyms:**

270 **PD** = Parkinson's disease; **VI** = visual impairment; **VA** = visual acuity; **LogMAR** =
271 logarithm of the minimum angle of resolution; **NHS** = National Health Service; **IQR** =
272 interquartile range; **HR** = hazard ratios; **CI** = confidence intervals; **SD** = standard
273 deviations; **PPV** = positive predictive value; **BMI** = body mass index

274

275 **Acknowledgements:** The present work was supported by the Fundamental Research
276 Funds of the State Key Laboratory of Ophthalmology, Project of Investigation on
277 Health Status of Employees in Financial Industry in Guangzhou, China (Z012014075),
278 Science and Technology Program of Guangzhou, China (202002020049). Prof.
279 Mingguang He receives support from the University of Melbourne at Research
280 Accelerator Program and the CERA Foundation. The Centre for Eye Research Australia
281 receives Operational Infrastructure Support from the Victorian State Government. The
282 sponsor or funding organization had no role in the design or conduct of this research.

283

284 **Potential Conflicts of Interest:** The author(s) have no potential conflicts of interest in
285 any materials discussed in this article.

286

287 Appendix 1. Author Contributions

Name	Location	Contribution
Zhuoting Zhu, MD PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Study concept and design; Drafting of the manuscript; Acquisition, analysis, or interpretation; Statistical analysis; Administrative, technical, or material support
Wenyi Hu, MBBS	Shanghai Jiaotong University, Shanghai, China	Study concept and design; Acquisition, analysis, or interpretation; Drafting of the manuscript
Huan Liao, MD	University of Bonn, Bonn, Germany	Study concept and design; Acquisition, analysis, or interpretation; Drafting of the manuscript
Zachary Tan, MBBS Mmed	University of Melbourne, Melbourne, Australia	Acquisition, analysis, or interpretation; Critical revision of the manuscript for important intellectual content
Yifan Chen, BM BCh	John Radcliffe Hospital, Oxford, UK	Acquisition, analysis, or interpretation; Critical revision of the manuscript for important intellectual content
Danli Shi, MD	Sun Yat-sen University, Guangzhou, China	Acquisition, analysis, or interpretation; Critical revision of the manuscript for important intellectual content
Xianwen Shang, PhD	University of Melbourne, Melbourne, Australia	Acquisition, analysis, or interpretation; Statistical analysis; Administrative, technical, or material support
Xueli Zhang, PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Acquisition, analysis, or interpretation

Yu Huang, MD PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Acquisition, interpretation	analysis,	or
Honghua Yu, MD PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Acquisition, interpretation	analysis,	or
Wei Wang, MD PhD	Sun Yat-sen University, Guangzhou, China	Acquisition, interpretation; Critical revision of the manuscript for important intellectual content; Administrative, technical, or material support	analysis,	or
Mingguang He, MD PhD	University Melbourne, Melbourne, Australia	of revision of the manuscript for important intellectual content; Obtained funding; Administrative, technical, or material support; Study supervision		
Xiaohong Yang, MD PhD	Guangdong Provincial People's Hospital, Guangzhou, China	Study concept and design; Critical revision of the manuscript for important intellectual content; Obtained funding; Administrative, technical, or material support; Study supervision		

288

289 **References:**

- 290 1. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of
291 Parkinson's disease: a review of the evidence. *Eur J Epidemiol* 2011;26 Suppl 1:S1-58.
- 292 2. Kalia LV, Lang AE. Parkinson's disease. *Lancet* 2015;386:896-912.
- 293 3. Collaborators GBDPsD. Global, regional, and national burden of Parkinson's disease, 1990-
294 2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*
295 2018;17:939-953.
- 296 4. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. *Nat Rev Dis Primers* 2017;3:17013.
- 297 5. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for
298 future Parkinson's disease. *Ann Neurol* 2008;63:167-173.
- 299 6. Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in
300 Parkinson disease without dementia. *Neurology* 2005;65:1907-1913.
- 301 7. Polo V, Satue M, Rodrigo MJ, et al. Visual dysfunction and its correlation with retinal changes
302 in patients with Parkinson's disease: an observational cross-sectional study. *BMJ Open*

-
- 303 2016;6:e009658.
- 304 8. Ming W, Palidis DJ, Spering M, McKeown MJ. Visual Contrast Sensitivity in Early-Stage
305 Parkinson's Disease. *Invest Ophthalmol Vis Sci* 2016;57:5696-5704.
- 306 9. Hamedani AG, Willis AW. Self-reported visual dysfunction in Parkinson disease: the Survey of
307 Health, Ageing and Retirement in Europe. *Eur J Neurol* 2020;27:484-489.
- 308 10. Nirmalan PK, John RK, Gothwal VK, et al. The impact of visual impairment on functional vision
309 of children in rural South India: the Kariapatti Pediatric Eye Evaluation Project. *Invest Ophthalmol*
310 *Vis Sci* 2004;45:3442-3445.
- 311 11. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the
312 causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015;12:e1001779.
- 313 12. Chua SYL, Thomas D, Allen N, et al. Cohort profile: design and methods in the eye and vision
314 consortium of UK Biobank. *BMJ Open* 2019;9:e025077.
- 315 13. Kathryn Bush KR, Tim Wilkinson, Christian Schnier and Cathie Sudlow On behalf of UK Biobank
316 Outcome Adjudication Group. Definitions of Parkinson' s Disease and the Major Causes of
317 Parkinsonism, UK Biobank Phase 1 Outcomes Adjudication. 2018. Available at:
318 https://biobank.ndph.ox.ac.uk/ukb/ukb/docs/alg_outcome_pdp.pdf [Accessed on September 30,
319 2020].
- 320 14. Qiu C, Hu G, Kivipelto M, et al. Association of blood pressure and hypertension with the risk
321 of Parkinson disease: the National FINRISK Study. *Hypertension* 2011;57:1094-1100.
- 322 15. Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson's disease. *Diabetes Care*
323 2011;34:910-915.
- 324 16. Kizza J, Lewington S, Mappin-Kasirer B, et al. Cardiovascular risk factors and Parkinson's
325 disease in 500,000 Chinese adults. *Ann Clin Transl Neurol* 2019;6:624-632.
- 326 17. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Exploring the Association Between Rosacea
327 and Parkinson Disease: A Danish Nationwide Cohort Study. *JAMA Neurol* 2016;73:529-534.
- 328 18. Guo L, Normando EM, Shah PA, De Groef L, Cordeiro MF. Oculo-visual abnormalities in
329 Parkinson's disease: Possible value as biomarkers. *Mov Disord* 2018;33:1390-1406.
- 330 19. Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction
331 of retinal dopaminergic circuitry in Parkinson's disease. *Surg Radiol Anat* 1988;10:137-144.
- 332 20. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease.
333 *Invest Ophthalmol Vis Sci* 1990;31:2473-2475.
- 334 21. Biehlmaier O, Alam M, Schmidt WJ. A rat model of Parkinsonism shows depletion of
335 dopamine in the retina. *Neurochem Int* 2007;50:189-195.
- 336 22. Ortuno-Lizaran I, Sanchez-Saez X, Lax P, et al. Dopaminergic Retinal Cell Loss and Visual
337 Dysfunction in Parkinson Disease. *Ann Neurol* 2020.
- 338 23. Marrocco E, Indrieri A, Esposito F, et al. alpha-synuclein overexpression in the retina leads to
339 vision impairment and degeneration of dopaminergic amacrine cells. *Sci Rep* 2020;10:9619.
- 340 24. Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR. Visual dysfunction in Parkinson's
341 disease. *Brain* 2016;139:2827-2843.
- 342 25. Firbank MJ, Parikh J, Murphy N, et al. Reduced occipital GABA in Parkinson disease with visual
343 hallucinations. *Neurology* 2018;91:e675-e685.
- 344 26. Armstrong RA. Visual Dysfunction in Parkinson's Disease. *Int Rev Neurobiol* 2017;134:921-
345 946.
- 346 27. Cheng D, Jenner AM, Shui G, et al. Lipid pathway alterations in Parkinson's disease primary

- 347 visual cortex. PLoS One 2011;6:e17299.
- 348 28. Ekker MS, Janssen S, Seppi K, et al. Ocular and visual disorders in Parkinson's disease:
349 Common but frequently overlooked. Parkinsonism Relat Disord 2017;40:1-10.
- 350 29. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet
351 2017;390:2183-2193.
- 352 30. Zhao J, Xu X, Ellwein LB, et al. Causes of Visual Impairment and Blindness in the 2006 and
353 2014 Nine-Province Surveys in Rural China. Am J Ophthalmol 2019;197:80-87.
- 354 31. Khan A, Petropoulos IN, Ponirakis G, Malik RA. Visual complications in diabetes mellitus:
355 beyond retinopathy. Diabet Med 2017;34:478-484.
- 356 32. Ramirez AI, de Hoz R, Salobarra-Garcia E, et al. The Role of Microglia in Retinal
357 Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma. Front Aging Neurosci
358 2017;9:214.
- 359 33. Brennan LA, Kantorow M. Mitochondrial function and redox control in the aging eye: role of
360 MsrA and other repair systems in cataract and macular degenerations. Exp Eye Res 2009;88:195-
361 203.
- 362 34. Zheng F, Yu M, Leung CK. Diagnostic criteria for detection of retinal nerve fibre layer thickness
363 and neuroretinal rim width abnormalities in glaucoma. Br J Ophthalmol 2020;104:270-275.
- 364 35. Sundstrom JM, Hernandez C, Weber SR, et al. Proteomic Analysis of Early Diabetic
365 Retinopathy Reveals Mediators of Neurodegenerative Brain Diseases. Invest Ophthalmol Vis Sci
366 2018;59:2264-2274.
- 367 36. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related
368 Characteristics of UK Biobank Participants With Those of the General Population. American Journal
369 of Epidemiology 2017;186:1026-1034.

370

371

372 Table 1. Baseline Characteristics of the Study Participants Stratified by Visual Impairment Status

Baseline Characteristics	Total	Non-VI Group	VI Group	P value
n	117,050	113,039	4,011	-
Age, mean (SD), yrs	56.8 (8.11)	56.8 (8.12)	58.8 (7.57)	<0.001
Gender, n (%)				0.361
Female	63,695 (54.4)	61,484 (54.4)	2,211 (55.1)	
Male	53,355 (45.6)	51,555 (45.6)	1,800 (44.9)	
Ethnicity, n (%)				<0.001
White	104,128 (89.0)	100,829 (89.2)	3,299 (82.3)	
Other	12,922 (11.0)	12,210 (10.8)	712 (17.7)	

Townsend deprivation index, mean (SD)	-0.93 (3.01)	-0.96 (3.00)	-0.12 (3.33)	<0.001
Smoking status, n (%)				<0.001
Never	64,503 (55.5)	62,314 (55.5)	2,189 (55.5)	
Former	40,014 (34.4)	38,750 (34.5)	1,264 (32.0)	
Current	11,744 (10.1)	11,252 (10.0)	492 (12.5)	
Drinking status, n (%)				<0.001
Never	6,215 (5.33)	5,877 (5.22)	338 (8.54)	
Former/current	110,352 (94.7)	106,731 (94.8)	3,621 (91.5)	
Obesity, n (%)				0.001
No	87,747 (75.4)	84,859 (75.5)	2,888 (73.1)	
Yes	28,640 (24.6)	27,576 (24.5)	1,064 (26.9)	
Physical Activity				0.378
Not meeting recommendation	16,831 (17.7)	16,259 (17.7)	572 (18.3)	
Above moderate/vigorous/walking recommendation	78,195 (82.3)	75,642 (82.3)	2,553 (81.7)	
History of stroke, n (%)				<0.001
No	115,275 (98.5)	111,368 (98.5)	3,907 (97.4)	
Yes	1,775 (1.52)	1,671 (1.48)	104 (2.59)	
History of diabetes, n (%)				<0.001
No	109,222 (93.3)	105,589 (93.4)	3,633 (90.6)	
Yes	7,828 (6.69)	7,450 (6.59)	378 (9.42)	
History of hypertension, n (%)				<0.001
No	29,940 (25.6)	29,113 (25.8)	827 (20.6)	
Yes	87,110 (74.4)	83,926 (74.2)	3,184 (79.4)	
Psychotropic medications, n(%)				0.052
No	107,982 (92.3)	104,314 (92.3)	3,668 (91.5)	
Yes	9,068 (7.75)	8,725 (7.72)	343 (8.55)	

373 SD = standard deviation; VI = visual impairment.

374

375

376 Table 2. Baseline Characteristics Stratified by Incident Parkinson Disease

Baseline Characteristics	Non-PD Group	PD Group	P value
N	116,828	222	-
Age, mean (SD), yrs	56.8 (8.11)	63.2 (5.42)	<0.001
Gender, n (%)			<0.001
Female	63,608 (54.5)	87 (39.2)	
Male	53,220 (45.5)	135 (60.8)	
Ethnicity, n (%)			0.452
White	103,927 (89.0)	201 (90.5)	
Others	12,901 (11.0)	21 (9.46)	
Townsend deprivation index, mean (SD)	-0.93 (3.01)	-1.16 (2.89)	0.258
Smoking status, n (%)			0.010
Never	64,389 (55.5)	114 (51.4)	
Former	39,919 (34.4)	95 (42.8)	
Current	11,731 (10.1)	13 (5.86)	
Drinking status, n (%)			0.123
Never	6,198 (5.33)	17 (7.66)	
Former/current	110,147 (94.7)	205 (92.3)	
Obesity, n (%)			0.153
No	87,591 (75.4)	156 (71.2)	
Yes	28,577 (24.6)	63 (28.8)	
Physical Activity			0.007
Not meeting recommendation	16,786 (17.7)	45 (25.4)	
Above moderate/vigorous/walking recommendation	78,063 (82.3)	132 (74.6)	
History of stroke, n (%)			0.369
No	115,058 (98.5)	217 (97.8)	

Yes	1,770 (1.52)	5 (2.25)	
History of diabetes, n (%)			0.054
No	109,022 (93.3)	200 (90.1)	
Yes	7,806 (6.68)	22 (9.91)	
History of hypertension, n (%)			0.023
No	29,898 (25.6)	42 (18.9)	
Yes	86,930 (74.4)	180 (81.1)	
Psychotropic medications, n(%)			<0.001
No	107,798 (92.3)	184 (82.9)	
Yes	9,030 (7.73)	38 (17.1)	

377 SD = standard deviation; PD = Parkinson's disease.

378

379

380 Table 3. Cox Proportional Hazards Models for Incident Parkinson Disease by Visual Impairment Status

VI Status	Age-, Gender- and Ethnicity-Adjusted		Multivariable Model ^a	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Main analysis				
VI status				
None	1 [Reference]	-	1 [Reference]	-
VI	2.13 (1.27-3.56)	0.004	2.28 (1.29-4.04)	0.005
Sensitivity analysis^b				
VI status				
None	1 [Reference]	-	1 [Reference]	-
VI	1.79 (1.05-3.03)	0.031	1.93 (1.07-3.49)	0.029

381 VI = visual impairment; PD = Parkinson's disease; HR = hazard ratio; CI = confidence interval.

382 ^a Cox proportional hazards regression models adjusted for age, gender, race/ethnicity, Townsend

383 deprivation index, smoking status, drinking status, obesity, physical activity, history of stroke, history

384 of diabetes, history of hypertension, and psychotropic medications.

385 ^b Excluding incident PD diagnosed in the year immediately following baseline assessment.

386

387